Blood biomarkers may replace risky biopsies for brain tumor patients
NCT ID NCT06104930
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at tiny particles in the blood (extracellular vesicles) from 60 meningioma patients who have had radiotherapy. The goal is to see if these particles can act as a 'liquid biopsy' to monitor the tumor and predict outcomes without needing a surgical biopsy. Researchers will track changes in these particles over time and compare them to tumor progression and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to monitor meningioma and guide treatment decisions without needing repeated biopsies.
What could go wrong
This is an early exploratory study with only 60 participants, so results may not be conclusive or widely applicable. The biomarker approach is still unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of Heidelberg, Radiation Oncology
RECRUITINGHeidelberg, 69120, Germany
Contact